Evidence map›Paper›PMID 30886615›Full record

ReviewFrontiers in immunology2019

Neutrophil Heterogeneity as Therapeutic Opportunity in Immune-Mediated Disease.

Ricardo Grieshaber-Bouyer, Peter A Nigrovic

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed.

  1. Trial
  2. Neutrophil Subset Immunophenotyping.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Multi‑omics reveal neutrophil heterogeneity in sepsis (Review).International journal of molecular medicine · 2025
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Neutrophils and NETs in kidney disease.Nature reviews. Nephrology · 2025
    Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ricardo Grieshaber-BouyerDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, United States.
Peter A NigrovicDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, United States.

Funding

Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
Ly6 family members in neutrophil biologyR01AR065538 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI NIGROVIC, PETER A · 2014 to 2024
$4.0M
Bridging the gap between GWAS and mechanism in JIAR01AR073201 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic · 2019 to 2026
$3.2M
NIAMS NIH HHS P30 AR070253NIAMS NIH HHS R01 AR065538NIAMS NIH HHS R01 AR073201
6 · The paper itself

Abstract

Neutrophils are versatile innate effector cells essential for immune defense but also responsible for pathologic inflammation. This dual role complicates therapeutic targeting. However, neither neutrophils themselves nor the mechanisms they employ in different forms of immune responses are homogeneous, offering possibilities for selective intervention. Here we review heterogeneity within the neutrophil population as well as in the pathways mediating neutrophil recruitment to inflamed tissues with a view to outlining opportunities for therapeutic manipulation in inflammatory disease.

Indexed as

Immune System DiseasesImmunity, InnateNeutrophil InfiltrationNeutrophilsHumansautoimmuneCD177granulopoiesisimmune mediated diseaseneutrophilneutrophil migrationtherapeutic opportunitiestherapeutic targeting

Identifiers

PMID30886615
PMCPMC6409342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.